NUCIEN PHARMA(SH:688189) Xin Lang Cai Jing·2025-09-12 04:23Company Overview - Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on December 27, 2006. The company was listed on March 26, 2020. Its main business focuses on the research, production, and sales of antiviral drugs for influenza and other infectious diseases, as well as treatments for major diseases such as cardiovascular diseases and diabetes. The revenue composition is entirely from chemical drug formulations, accounting for 100% [1]. Stock Performance - As of September 12, Nanjing Pharmaceutical's stock price decreased by 2.07%, trading at 12.75 CNY per share, with a total market capitalization of 3.499 billion CNY. The stock has increased by 94.95% year-to-date, but has seen a decline of 7.47% in the last five trading days and 5.42% in the last 20 days. Over the past 60 days, the stock has risen by 77.33% [1]. - The company has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on August 27, where it recorded a net buy of 104 million CNY, accounting for 30.60% of total trading volume [1]. Financial Performance - For the first half of 2025, Nanjing Pharmaceutical reported a revenue of 61.8463 million CNY, a year-on-year decrease of 71.28%. The net profit attributable to the parent company was -40.0023 million CNY, reflecting a significant decline of 493.23% compared to the previous period [2]. - The company has cumulatively distributed 40.74 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.02% to 9,464, while the average number of tradable shares per person decreased by 6.56% to 28,994 shares [2]. - Among the top ten circulating shareholders, Dazheng Jingheng Mixed A (090019) holds 2.9738 million shares, with no change in the number of shares held compared to the previous period [3].